| |
Whew what a disaster, unless you were short yesterday… | Nevertheless, here are today's biggest (positive) movers (yes, there are some!). Don't forget to join us in Market Masters - lick your wounds with us in there 😵! | | FOCUS LIST🔎 | SLGL - Up over 49% in the pre-market after announcing the signing of six exclusive license agreements to commercialize TWYNEO® and EPSOLAY® in Europe and South Africa | MIRA - Up over 40% in pre after announcing positive discovery of Ketamir-2's selective NMDA Binding Mechanism of Action | POAI - Up over 12% in pre after announcing its entry into the biomarker discovery market after successful retrospective ovarian cancer study yields compelling results | | *sponsored by Awareness Consulting Network | Despite the massive CARNAGE yesterday, I continue to see a lot of great opportunities when it comes to smaller momentum stocks. | Just like Tuesday's idea, which gained 17%, or today's idea that's up another 10% today in pre-market trading. | Pull up Kindly MD, Inc. (KDLY) and I'll show you what I am seeing. | First of all, KDLY is a recent IPO. It started trading at the end of May, and not a lot of people are following this stock, yet. | The trading hasn't been too exciting so far as it was down nearly 50% from the peak at one point a couple of weeks ago. | However, since that low point, the volume has picked up and the stock has been on a tear and is up over 35% since last week. | Look at this chart showing the strong move KDLY has made recently... | | This is especially significant in the face of a horrendous overall market. | That is what I call real strength, and you should pay attention to it. | Right now is a crucial moment for KDLY though. | Make sure to do your own due diligence if you decide to trade it. To see my full report on Kindly, visit this page here. | And keep KDLY on your radar today! | *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. |
|
| | HOTLIST🔥 | SLGL - Up over 49% in the pre-market after announcing the signing of six exclusive license agreements to commercialize TWYNEO® and EPSOLAY® in Europe and South Africa | Sol-Gel Technologies Ltd. (SLGL) develops topical dermatological drugs for patients with severe skin conditions in Israel. | In the pre-market this morning, the company announced the signing of six exclusive license agreements to commercialize TWYNEO® and EPSOLAY® in Europe and South Africa. | TWYNEO® for the treatment of acne vulgaris and EPSOLAY® for the treatment of inflammatory lesions of rosacea. SLGL has entered into six (6) exclusive license agreements with MagnaPharm Trading Slovakia S.R.L, Galenica A.B, Leman SKL SA, InfectoPharm, Aspire Pharma Limited and Abex Pharmaceutica (PTY) Ltd. for the commercialization of TWYNEO and EPOSLAY covering the majority of the European countries. | Sol-Gel to receive upfront and regulatory milestone payments totaling in up to low 7-digit USD and either fixed transfer sale price or low double-digit royalties from net sales; payments are backed by commitments to minimum annual sales. | The stock traded up over 49% in the pre-market in reaction to the news. | | The $0.80 level acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $1 and then the pre-market high at $1.14. Beyond that, $1.20, $1.30 and $1.44 come into play. | Below $0.80, targets to the downside are $0.72 and then a gap fill at $0.67. | | MIRA - Up over 40% in pre after announcing positive discovery of Ketamir-2's selective NMDA Binding Mechanism of Action | MIRA Pharmaceuticals Inc. (MIRA) operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. | In the pre-market this morning, the company announced new insights garnered from additional, recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2. | Ketamir-2 is MIRA's drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders. | The latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the PCP-binding site of the NMDA complex. Ketamir-2 has a 30-50-fold lower affinity to the PCP site compared with ketamine. | The lower affinity is important because at high affinity, compounds may affect neurobehavioral functions, potentially leading to side effects such as dissociation and hallucinations. | This selectivity is notable as it may contribute to a distinct pharmacological profile for Ketamir-2, potentially reducing the risk of side effects associated with these other interactions. | The stock traded up over 40% in the pre-market in reaction to the positive findings. | | The first target for bulls is the pre-market high at $3.78. | Beyond that, $4.12, $4.50 and $5.01 come into play. | Below $3.78, targets to the downside are $3.25, $2.88, $2.60, $2.40 and then a gap fill at $2.36. | | POAI - Up over 12% in pre after announcing its entry into the biomarker discovery market after successful retrospective ovarian cancer study yields compelling results | Predictive Oncology Inc. (POAI) is a knowledge and science-driven company that applies artificial intelligence (AI) to support the discovery and development of optimal cancer therapies. | In the pre-market this morning the company announced that it is expanding its AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology. | Predictive Oncology's biomarker discovery initiative stems, in part, from results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital, which were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. | In that study, Predictive Oncology successfully developed muti-omic machine learning models that identified key features that could more accurately predict both short-term (two-year) and long-term (five-year) survival outcomes among ovarian cancer patients as compared to clinical data alone. | Through this process, Predictive Oncology obtained and analyzed data that supports novel ovarian cancer biomarker discovery and development that will be further explored both independently and in partnership with biopharma companies. | Arlette H. Uihlein, MD, SVP, Translational Medicine and Drug Discovery and Medical Director at Predictive Oncology stated: | "We believe the identification of novel cancer biomarkers represents the next significant opportunity for the application of our platform, which leverages the substantial value inherent in the diversified patient samples and data that we possess, as well as additional potential revenue streams for our company. | The stock traded up over 12% in the pre-market in reaction to the press release. | | The first target for bulls is $1.25 and then the pre-market high at $1.30. | Beyond that $1.40, $1.50 and $1.80 come into play. | Below $1.25, targets to the downside are $1.15, $1.10 and then a gap fill at $1.07. | | MARKET NEWS 📰 | | P.S. Make sure you text "RAGE" to (888) 404-5747 to get all of our latest HOT STOCK ideas! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | *Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call "typical." | Just a quick heads up about this ad you're reading—as we've said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty thousand dollars (cash) from Awareness Consulting Network for advertising Kindly MD, Inc for a one day marketing program on July 25, 2024. This amount was paid by someone else not connected to Kindly MD, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case. | Now, diving right into Kindly MD, Inc might sound exciting. But remember, it's like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you're doing. That's why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r. | Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We're simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We're obviously biased in our writing. We're not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as "forward-L00king statements" under the securities acts, so take those with a grain of salt. As with all forecasts, they're not set in stone, often wrong, and we certainly can't know where the Company's earnings, business, or share price will be tomorrow or a year from now. | Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, | Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep's with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization. | So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture. |
|
|
|
Post a Comment
Post a Comment